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Emanuel Paionni1, Patrizia Paterna1, Elena Dellambra1, Lidia Larizza2 and Liliana Guerra1
Piebald trait leukoderma results from ‘‘loss-of-function’’ mutations in the kit gene. Correlations between
mutation type and clinical phenotype have been reported. However, mutation classification has been mainly
based on the clinical features of patients. The aim of this study was to get a better understanding of the
pathogenesis of human piebaldism by establishing whether the kit mutation type may affect the in vitro
survival/proliferation of patient melanocytes. Overall, the research was finalized to implement the clinical
application of the autologous cultured epidermis in the treatment of piebald patients. Seven patients, who were
transplanted with autologous in vitro reconstituted epidermis, showed an average percentage of repigmenta-
tion of 90.7. Six novel and one previously reported mutations were found and their postulated effects discussed
in relation to the clinical phenotype and in vitro behavior of epidermal cells. Although mutation type did not
impair repigmentation given by autotransplantation, it was shown to influence the survival/proliferation of co-
cultured melanocytes and keratinocytes. In particular, tyrosine kinase domain mutations were found with
melanocyte loss and keratinocyte senescence during expansion of epidermal cultures. Results indicate that the
clinical application of cultured epidermis in piebald patients may be optimized by investigating mutation
functional effects before planning surgical operations.
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INTRODUCTION
Piebald trait (MIM no. 172800) is an autosomal dominantly
inherited leukoderma typically affecting the forehead, ante-
rior trunk, and central extremities.
Human piebaldism results from constitutional heterozygous
‘‘loss-of-function’’ mutations in the kit gene, which encodes the
cell surface transmembrane tyrosine kinase (TK) receptor for KIT
ligand (stem cell growth factor (SCF), mast cell growth factor, or
steel factor) (Spritz, 1997, 2006; Murakami et al., 2004, 2005).
In the skin, SCF is produced by fibroblasts and keratinocytes
(Brenner et al., 2005; Okazaki et al., 2005) and stimulates the
KIT receptor expressed on melanoblasts/melanocytes and mast
cells (Longley et al., 1993; Grichnik et al., 1998; Ito et al., 1999;
Botchkareva et al., 2001; Kunisada et al., 1998, 2001).
Deficient KIT-dependent signaling results in a primary
defect of migration of neural crest melanoblasts to the skin
during embryogenesis and interferes with local migration
of skin melanoblasts and melanocytes during postnatal life
(Alexeev and Yoon, 2006; Grichnik, 2006; Spritz, 2006). KIT-
dependent signaling also seems to be required for melano-
blast/melanocyte survival and proliferation (Botchkareva
et al., 2001; Kunisada et al., 2001; Alexeev and Yoon,
2006; Grichnik, 2006; Spritz, 2006).
Heterozygous mutations in the kit gene have been
demonstrated in about 75% of patients with piebaldism
(Ezoe et al., 1995; Murakami et al., 2005), with a fairly good
correlation between mutation site and type and severity of the
resulting clinical phenotype (Spritz, 1997).
Medical therapies of piebaldism cannot be successful due
to the lack of epidermal/hair follicle melanocytes within the
achromic areas, where melanocytes have to be introduced by
surgical techniques (Falabella et al., 1995; Njoo et al., 1998;
Olsson and Juhlin, 2002). Emerging technologies based on
autologous cell therapy are important alternatives to conven-
tional surgical methods in the treatment of this mendelian
disease (Falabella et al., 1995; Kumagai and Uchikoshi,
1997; Olsson and Juhlin, 2002; Guerra et al., 2004).
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We have recently reported that the autologous cultured
epidermis bearing melanocytes induces high levels of
repigmentation in piebaldism, comparable to the highest
success rate achieved by split-thickness skin grafts or
epidermal blister grafts (Guerra et al., 2004). Moreover, we
have shown that the melanocyte to keratinocyte (M/K) ratio
can be monitored in the in vitro reconstituted epidermis
(Guerra et al., 2000, 2003, 2004), and that an almost
complete/fully complete repigmentation may be assured by a
M/K ratio in vitro ranging from 1/40 to 1/400 (Guerra et al.,
2000, 2003, 2004).
Several considerations prompted us to choose the in vitro
reconstituted epidermis bearing melanocytes for the treatment
of some pigmentary disorders, such as vitiligo and piebaldism.
Indeed, in the cultured epidermal sheet, keratino-
cytes regulate melanocyte growth and differentiation (De
Luca et al., 1994; Vancoillie et al., 1999), and the proper M/K
ratio (De Luca et al., 1988, 1994; Guerra et al., 2000, 2003,
2004). Melanocytes home into the basal layer of the cultured
epidermis, develop dendrite arborization with melanosome-
containing processes and transfer melanosomes into basal
keratinocytes (Seiberg, 2001), being hence able to maintain
their physiological characteristics when co-cultured with
keratinocytes.
It has been also demonstrated that, if keratinocytes are
subcultured 1–2 days after they reach confluence and seeded
at high cell density, the M/K ratio is several fold higher than
under conditions that privilege colony forming ability and
stem cell maintenance (i.e. passaged during the exponential
phase of growth) (De Luca et al., 1988; Guerra et al., 2000).
In particular, the M/K ratio observed in secondary cultures,
that is, in cultures eventually destined to transplantation, is
particularly favorable (Guerra et al., 2000, 2003, 2004) and
can be preserved during repeated subcultivation (De Luca
et al., 1988; Guerra et al., 2000).
Based on this experience, we planned to carry out further
operations in piebald trait patients, by subcultivating pre-
viously frozen cells, in order to greatly amplify the epidermal
cell population isolated from the original skin biopsy. Here,
we report that we detected a progressive loss of melanocytes
in three out of five tertiary cultures destined to the second
transplantation, a finding that made it necessary to perform
an additional skin biopsy in the three above-mentioned
patients. In order to be able to evaluate different results
achieved from different cases, we (i) investigated factors
influencing the melanocyte survival in cultures destined to
transplantations and (ii) performed long-term follow-up visits
in seven piebald trait patients, who underwent one to two
surgical operations for the treatment of their disease. In
parallel, we tested all the patients for kit gene mutations and
investigated the in vitro behavior of their epidermal cells
(melanocytes and keratinocytes) by culturing them till
senescence. Results obtained point to a correlation between
the ‘‘grade’’ of kit mutation, as inferred by both intragenic
location/type, and effect on the overall presentation of the
patient and on the feasibility of the clinical application of the
in vitro reconstituted epidermis in the surgical treatment of
the pathology.
RESULTS
Transplant outcome in the investigated patients
Patients’ clinical and biological data are shown in Table 1.
P129, P154, and P185 patients, who were treated twice,
underwent two skin biopsies, because we did not manage to
maintain melanocytes in tertiary cultures in order to treat a
larger area.
On the contrary, we successfully treated P169 (twice) and
P160 (three times) patients in subsequent transplantation
procedures, starting from frozen cells that had been isolated
from the original skin biopsy. P161 patient did not need
further operations. All the remaining patients are awaiting
further operations.
As shown in Table 1, the average percentage of
repigmentation in our patients was 90.7 (4,867.7 repigmen-
ted cm2/5,364.4 transplanted cm2). Figure 1 shows trans-
planted areas in P169 (Figure 1a–d) and P185 (Figure 1e and
f) patients, 12 months after autotransplantation.
In abdominal areas of P160 and P154 patients, the
take of autografts was not complete, owing to the difficulty
for patients to maintain an adequate immobilization
in bed.
Variation of the M/K ratio in cultured grafts within the 1/
36–1/417 range (Table 1) was not correlated to the percentage
of final repigmentation, nor with the intensity of repigmenta-
tion. Repigmentation was stable within 18–60 months, as
indicated by the follow-up column in Table 1.
Different in vitro lifespan of melanocytes/keratinocytes from
the investigated patients
In order to investigate the melanocyte survival in the in vitro
reconstituted epidermis from piebaldism patients, we per-
formed serial expansion of epidermal cells until they reached
senescence.
As shown in Figure 2a, the melanocyte survival/prolifera-
tion was not affected in the serially expanded in vitro
reconstituted epidermis from P161 and P160 piebald
patients, as indicated by M/K ratios equal to 1/168 and
1/95, respectively, at the end of cell lifespan. The M/K ratio
in the cultured epidermis from P169 and P181 patients
was also preserved during in vitro passages, even if at lower
levels (1/421 and 1/311, respectively). On the contrary, a
rapidly decreasing M/K ratio starting from the third passage
(1/2.000–1/48.000) was seen in cultures from P129, P154,
and P185 patients (Figure 2a). An average M/K ratio of 1/59
was shown at the end of the lifespan in control cultures
(Figure 2b).
Unexpectedly, an impaired behavior of keratinocytes from
piebald trait patients was detected during their in vitro
lifespan. Piebaldism keratinocytes in confluent culture con-
ditions underwent an average value of 38.8476.14 cell
doublings (Figure 2c), without particular differences among
mild, moderate, and severe patients, whereas control
keratinocytes performed an average value of 54.477.91 cell
doublings (Figure 2d). It is not surprising that keratinocytes
cultivated under conditions that privilege melanocyte growth
(keratinocytes sub-cultivated at least 1 day after confluence)
possess a lower cell doubling number than keratinocytes
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cultivated under conditions that privilege stem cell main-
tenance (keratinocytes passaged during the exponential
phase of growth) (Pellegrini et al., 1999), because the latter
culture system is aimed at permanent epidermal regeneration
in massive full-thickness burns (Pellegrini et al., 1999;
Ronfard et al., 2000). Indeed, piebald keratinocytes in
subconfluent culture conditions underwent an average value
of 69.97716.35 cell doublings, which however remains
Table 1. Clinical and biological data of 7 piebald trait patients, treated by means of the autologous in vitro
reconstituted epidermis
Patient
Phototype/
age
(years)/
sex,
phenotype
Affected
body
sites
Affected
family
members
Number
of skin
biopsies/
number of
operations
Melanocyte/
keratino-
cyte ratio
in auto-
grafts
Treated
body
areas
cm2 of
treated
areas
(total
treated
areas)
cm2 of
repigmented
areas (total
repigmented
areas)
Percentage
of
repigmen-
tation
(average
percentage)
Total cm2 of
recipient
area/total
cm2 of
donor
area
(amplifica-
tion folds)
Last
follow-
up visit
(months)
1
P161
IV/16/F,
mild
WF,
left leg
WF: mother;
sister,
brother
1/1 1:68 Left leg
(front)
no need of
further grafts
107.78 107.78 100% 107.7/1.5
(71.8)
48
2
P169
II/20/M,
moderate
WF,
forehead,
knees,
and legs
P: maternal
grandfather
WF: mother,
maternal
great-
grandmother
1/2 1:55
1:136
Left knee
and leg
(front)
Legs (back)
466.37
394.93
(861.3)
433.894
387.03
(820.924)
93%
98%
(95.3%)
861.3/2
(430.6)
48
36
3
P181
II/32/M,
moderate
WF,
forehead,
knees, and
legs
P: paternal
grandmother,
father,
paternal
aunt
1/1 1:36 Knees and
legs (front)
413 392.35 95% 413/3
(137.6)
18
4
P160
II/12/M,
moderate
WF,
forehead,
abdomen,
midthighs to
midcalves
NI 1/3 1:43
1:48
1:126
Legs (front)
Legs (back)
Abdomen
320
380
435.53
(1135.53)
320
368.4
326.64
(1011.44)
100%
96%
75%
(89.07%)
1135.5/1.5
(757)
60
36
24
5
P129
III/21/F,
severe
WF,
forehead,
chest,
abdomen,
mid-upper
arms to wrists,
midthighs to
midcalves
P: father 2/2 1:417
1:169
Right leg
(front)
Forehead
Chest
193.35
40
670
(903.35)
183.68
39.2
636.5
(859.38)
95%
98%
95%
(95.13%)
193.3/1.2
(161)
710/3
(236.6)
60
48
6
P154
III/27/M,
severe
WF,
forehead,
chest,
abdomen,
mid-upper
arms to wrists,
midthighs to
midcalves
P: father 2/2 1:342
1:195
Chest
Abdomen
Left forearm
563.24
213.85
187.15
(964.24)
506.916
53.46
159.07
(719.446)
90%
25%
85%
(74.61%)
563.2/2.2
(256)
401/3.3
(121.5)
60
48
7
P185
II/29/M,
severe
WF,
forehead,
chest,
abdomen,
mid-upper
arms to
wrists,
midthighs to
midcalves
P: paternal
grandmother,
father, sister,
first cousin
2/2 1:169
1:228
Chest
Abdomen
636.34
342.94
(979.28)
623.613
329.222
(952.835)
98%
96%
(97.29%)
636.3/3.4
(187)
342.9/3
(114.3)
30
18
Total values 5364.4 4867.7 90.7%
F, female; M, male; NI, not identified; P, piebaldism; WF, white forelock.
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significantly lower than that of 120720 cell doublings
observed in control keratinocytes in comparable culture
conditions (data not shown) (Pellegrini et al., 1999; Maurelli
et al., 2006).
Furthermore, all piebaldism keratinocyte cultures showed
a rapid decrease of their colony forming efficiency (CFE)
(Figure 2e) and a similarly rapid increase of the percentage of
aborted colonies (Figure 2g). In contrast, both the naturally
occurring decrease of the CFE and increase of the percentage
of aborted colonies were more gradual in control keratino-
cyte cultures (Figure 2f and 2h).
Proliferation, differentiation, and senescence markers in
cultured epidermal cells
The impaired behavior of cultured keratinocytes from piebald
trait patients, prompted us to analyze proliferation, differ-
entiation, and senescence marker expression in the in vitro
reconstituted epidermis by Western blot.
As shown in Figure 3a, SCF expression was slightly
upregulated in cultures from piebald trait patients. The
expression level of p63, a marker of proliferative potential
in epithelial cells, was comparable between control keratino-
cytes and piebald trait keratinocytes, except for P160
cultures, whose p63 expression was lower.
As previously described (Dellambra et al., 2000), the
senescence marker p16 was undetectable in control and
piebald keratinocytes, except for P160 cultures, where p16
expression was higher. Lower levels of the tumor suppressor
gene p53 and its effector p21 were detected in severe piebald
trait patients. Differentiation markers such as involucrin and
14-3-3s (Figure 3b) were similarly expressed in piebaldism
patients and control cultures.
Mutational analysis
Direct sequencing of the proto-oncogene c-kit in seven
piebald patients allowed to identify the pathogenetic muta-
tions in all of them: they include six novel mutations and one
(M541L in P160 patient) previously reported (Murakami
et al., 2004). Figure 4 shows an overview of the mutations
that are mapped on the kit-cDNA and the predicted
outcomes at the KIT receptor. The consequences of the
mutations on KIT functioning are also indicated and inserted
in the literature context. Last, the phenotype of the carrier
patients, which is considered to be the ultimate effect of the
mutation, is reported.
In detail, P161 and P169 patients were found to carry
two different frameshift mutations: P161 at the 50-terminus
(30dupT) in exon 1, which leads 45 codons downstream
(exon 2) to a translational truncation; P169 in exon 16
encoding the second TK domain ((2334_2336)delG), which
leads 34 codons downstream (exon 17) to a translational
truncation. Both mutations could lead to haploinsufficiency
by nonsense-mediated decay of the kit transcripts containing
a premature stop codon. Should the nonsense-mediated
decay be inefficient, the 30dupT mutation is predicted to give
rise to a defective KIT polypeptide truncated at the ligand-
binding domain, determining in any case a 50% loss of
function, in accordance with the mild phenotype of P161
patient. Conversely, the distal frameshift mutation
(2334_2336)delG should result in termination of translation
in TK2 domain, which leads to a combination of loss of
function and dominant-negative effects (depending on the
stability of the truncated transcripts and polypeptides). This
results in a more complex phenotype, as in the case of P169
patient. Consistent with this prediction, a similar distal
frameshift mutation affecting exon 16 was previously
a b
c d
e f
Figure 1. Results of cultured epidermal cell autotransplantation in two
patients. (a) and (b) Depigmented areas of back of legs in P169 patient in
normal (a) and Wood (b) light. (c and d) A 98% repigmentation was evaluated
at the 12-month follow-up visit. The esthetic appearance of the almost
completely repigmented area was improved by dyeing the leg hair, which the
patient began to do 1 year after the transplantation. (e) Large leukodermic
area of the chest and abdomen in P185 patient. (f) A 97% repigmentation
was shown at the 12-month follow-up visit. Hyperpigmentation explains the
non-homogeneous appearance of the treated areas: areas of pre-existing
normally pigmented skin (arrows) are present within the darker transplanted
regions. Our experience, however, suggests that this effect is transitory
and does not require medical therapies.
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described in association with moderate phenotype (Muraka-
mi et al., 2004).
P181 patient, who displayed a moderate phenotype, was
found to carry a new terminal frameshift mutation in exon 21
(2921_2922delAC), which shifts the stop-codon 71 residues
downstream, leading to an elongated protein. We might
hypothesize that the modified protein could enter the
membrane bilayer and interfere with the KIT receptor
function by changing, following frameshift, the specific
terminal amino-acid motif HDDDV, and possibly altering
its 3D structure. Interestingly, this KIT receptor terminal motif
provides a binding site for the 10th PDZ (Postsynaptic density
protein, Disk large, Zonula occludens) domain of MUPP-1
protein, which has been thought to enhance SCF-mediated
signaling cascades (Mancini et al., 2000).
In P160 patient, who also showed a moderate pheno-
type, we found a missense mutation in exon 10 (M541L),
which has been reported previously (Murakami et al.,
2004). As proposed by the authors, this mutation
possibly impairs insertion of the KIT receptor in the cell
membrane or may affect dimerization of the receptor
polypeptide.
Moving to mutations correlated to severe phenotype, we
identified the A621S mutation in P154 patient. The same
codon was altered by the A621T change in a Bangladeshi
patient, who also showed a severe piebaldism (Ezoe et al.,
1995). A621S and A621T exert a similar effect at protein
level, both replacing a nonpolar highly conserved amino acid
(Ala) with an uncharged polar amino acid of hydroxyl group
(Ser/Thr).
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Figure 2. Biological data from serially expanded epidermal cells. (a, c, e, g) Cultures from piebald trait patients. (b, d, f, h) Cultures from controls. The
blue, black, and red lines indicate mild, moderate, and severe piebald trait patients, respectively. (a, b) M/K ratio in cultured epidermal cells. (c and d)
Cell doubling performed by cultured cells during serial amplification. (e, f) Percentage of total colonies (calculated on total plated keratinocytes).
(g, h) Percentage of aborted colonies (calculated on total colonies).
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P129 and P185 patients were heterozygous for two novel
mutations affecting splice-site junctions, represented by one
base insertion at consensus sequence near IVS12 donor site
(IVS12þ 3insT), and by a transition at the IVS 12 acceptor site
(IVS12-1G4A), respectively.
Splicing effects of IVS12þ 3insT were evaluated by
applying three different splicing prediction programs on the
sequence surrounding the IVS12 splice donor (from exon 11
to exon 13): Neural Network (http://www.fruitfly.org/
seq_tools/splice.html), Splice View (http://125.itba.mi.cnr.it/
Bwebgene/wwwspliceview.html), and NatGene2 (http://
www.cbs.dtu.dk/services/NetGene2). All three computer-
assisted splice-site predictions identify the legitimate 50
IVS12 splice site of wild-type sequence with a score
exceeding the respective thresholds, whereas they fail to
detect any splice donor for the mutant sequence.
We assume that the effects of IVS12þ 3T mutation are
assimilable to those predicted by Spritz for the
IVS12þ 1G4A mutation, which was identified in a proband
with severe piebaldism (Spritz et al., 1992). The author
ascribes to this mutation a very complex combination of loss
of function and dominant-negative effects leading to a
50–75% reduction of Kit function, responsible for the highly
variable phenotypes observed in affected family members.
The same interpretation holds for IVS12-1G4A mutation,
detected in the severely affected P185 patient, where the
lack of IVS12 acceptor splice could cause missplicing
through (i) IVS12 retention, leading to a premature truncated
KIT polypeptide, in case the transcript is not subjected
to nonsense-mediated decay, and/or (ii) exon 13 skipping
(111 bp), giving rise to an aberrant polypeptide with
an in frame deletion of 37 amino acids in the first TK
domain.
The apparent correlation between mutations and overall
clinical phenotype also applies to the in vitro melanocyte
lifespan. If we examine Figure 2a, it results that melanocyte
survival/proliferation was not particularly affected in the
serially expanded in vitro reconstituted epidermis from
patients showing a mild-moderate phenotype (P161, P160,
P169, P181), who were found to carry mutations with a
prevalent loss-of-function effect. In contrast, the severely
affected patients (P154, P129, P185), showing mutations that
were predicted to have prevalent dominant-negative effects,
are associated with a lack of melanocytes at the end of the
in vitro lifespan of their cultured epidermis.
DISCUSSION
The identification of pathogenetic mutations of the kit gene in
about 75% of piebald trait patients clearly indicated that KIT-
dependent signaling plays key roles in melanoblast/melano-
cyte migration, maintenance and survival in both prenatal
and postnatal life (Spritz, 2006). This is also attested by
studies of in vitro proliferation of melanocytes carrying loss-
of-function mutations (Spritz et al., 1994).
The KIT protein, a member of the TK family of
transmembrane receptors, undergoes dimerization within
the cell membrane upon SCF binding to its extracellular
domain, thus activating its intracellular TK (Spritz, 1997).
Loss-of-function mutations result in haploinsufficiency or
dominant-negative effects, at levels depending on the nature
of the mutation and location at different receptor domains.
The following hierarchical ranking of the mutations has been
proposed.
Missense mutations in the intracellular TK1 domain
correlate with severe piebald phenotypes, because of full
dominant-negative inhibition of the KIT receptor via forma-
tion of impaired receptor heterodimers between a normal and
a mutant KIT monomer, and a 75% decrease of KIT-
dependent signal transduction (Spritz, 1997).
Proximal frameshifts and missense mutations are by
contrast associated with a mild piebald phenotype, the result
of pure haploinsufficiency owing to a 50% decrease of KIT-
dependent signal transduction (Spritz, 1997).
Within these two ends of the spectrum fall the distal
frameshifts and splice junction mutations located near the
intracellular TK1 domain. These are mainly associated with
variable phenotypes, as the distally truncated polypeptides,
via incorporation into non-functional receptor heterodimers,
would decrease KIT-dependent signal transduction by
50–75%. Indeed, although these mutations abolish expression
of fully functional KIT receptor, some truncated KIT receptors
can still bind SCF and even form dimers. These inhibit
function of the product of the normal allele by a dominant
negative effect. However, as both the incompletely translated
KIT mRNA and the truncated KIT polypeptide are probably
unstable, they are likely to be present at less than a full dose
(partial dominant-negative effect) (Spritz, 1997).
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Figure 3. Western blot analysis of cultured epidermal cells. Confluent
epidermal cultures from controls (c140, c146) and piebald trait patients
(P161, P169, P181, P160, P129, P154, P185) have been analyzed. (a) SCF,
proliferation (p63) and senescence (p16, p53, p21) markers were analyzed.
GA3PDH was our loading control. (b) Differentiative (involucrin, 14-3-3 s)
markers were analyzed. GA3PDH was our loading control.
www.jidonline.org 681
S Bondanza et al.
kit Mutation and Piebald Melanocyte Survival
Such mutation classification has been mainly based on the
clinical phenotype of the patients, as proliferation studies of
defective melanocytes have only been performed sporadi-
cally, whereas functional KIT-dependent transduction studies
have only been designed for a few activating c-kit mutations.
This study provides new hints on the biological rationale
of autotransplantation in piebald patients carrying different
c-kit mutation. First, the success rate with transplantation
procedures is shown to be very high, approaching 90%,
regardless of the overall phenotype, the severity of mutation
and the survival/proliferation of co-cultured melanocytes and
keratinocytes. The satisfactory repigmentation rate was
confirmed to be stable until 5 years after transplantation.
The appropriate and complex cytokine environment that
exists in vivo is most probably the critical factor for
melanocyte proliferation and survival after autografting
(Grichnik, 2006).
In addition, the results achieved confirm that the type of kit
mutation fairly correlates with the clinical phenotype of the
patients and also may be interpreted in its functional effect
by the pattern of proliferation and survival of patients’
melanocytes in vitro. Analyses focused on transcripts
and the activation status of KIT-dependent signaling
translation should be designed to validate the above
statement. However, the proliferation studies of KIT defective
melanocytes have represented a complementary valuable
approach.
Unexpectedly, keratinocyte cultures from piebald
trait patients showed a shorter lifespan than those from
healthy controls, the former having performed a lower
number of total cell doublings. Obviously, a more rapid
clonal evolution (i.e. the passage from stem cells to transient
amplifying cells, which gradually occurs during natural
aging, wound healing and keratinocyte subcultivation) was
indicated by the quick decrease of total colonies and increase
of aborted ones. Furthermore, p53 and p21 downregulation
in cultured keratinocytes from severe piebald trait patients
suggests an accelerated cell senescence (Munro et al., 1999;
Rheinwald et al., 2002; Maurelli et al., 2006). These data are
consistent with an impaired behavior of cultured keratino-
cytes too, even if these cells are not primarily affected by the
KIT dysfunction.
Melanocytes and mast cells are thought to be the only
cutaneous cells, which express c-KIT. However, intriguing
recent studies in mice suggest the existence of a population
of KIT-positive hair matrix keratinocytes (Peters et al.,
2003), pinpointing a possible new function of KIT signaling
in epithelial cell biology. The authors hypothesize that
KIT-positive cells seen in the most proximal anagen
hair bulb might represent a particularly rapidly proliferating
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
cDNA Mutation site KIT receptor Predicted protein Predicted effect Reported
mutations
Haploinsufficiency
Haploinsufficiency
or partial DN
P161: absent/truncated at 55P161: frameshift 30 dupT (cod.10)
P160: missense 1621A>T (cod. 541) P160: M541L
SS
EC
TM
JM
TK1
TK2
KI
Altered function
Altered function
(M541L)1
Full DN
Partial DN
(A621T)2
(IVS12+1G>A)s
P154: missense 1861G>C (cod. 621) P154: A621S
P129: absent/truncated at 628aa/35aa missing in TK1
P185: absent/truncated at 637aa/37aa missing in TK1
P169: absent/truncated at 813
P129: splicing IVS12+3insT
P185: splicing IVS12-1G>A
P169: frameshift (2334–2336)delG (cod. 779)
P181: frameshift 2921_2922delAC (cod. 974) P181: Frameshift of 3aa and elongation of 71
Figure 4. Mapping to kit cDNA and KIT receptor of the seven identified mutations. Three frameshift, two missense, and two splicing mutations have been
identified. The blue, black, and red colors indicate mild, moderate, and severe phenotype of the carrier patients, respectively. The envisaged effects of the
mutations and literature for identical or similar mutations are also provided (1: Murakami et al., 2004; 2: Ezoe et al., 1995; 3: Spritz et al., 1992). SS: Signal
sequence (aa 1–22), EC: Extracellular domain (aa 23–520), TM: Transmembrane domain (aa 521–543), JM: juxtamembrane domain (aa 544–581), TK1: TK
domain 1 (aa 582–684), KI: Kinase insert domain (aa 685–761), TK2: TK domain 2 (aa 762–937). DN: Dominant-negative effect.
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sub-population of follicle transient amplifying keratinocytes,
which depend on SCF/KIT signaling for proliferation
and undergo terminal differentiation or apoptosis when
signaling is downregulated during hair follicle regression
(Peters et al., 2003). Thus, SCF, which is also expressed
by these KIT positive keratinocytes, becomes an important
paracrine and autocrine regulatory factor for selected
epithelial cells.
We speculate that keratinocyte contiguity to KIT-expres-
sing melanocytes in the skin compartment might induce
keratinocyte suffering in piebald trait patients, via an
impaired SCF/KIT interaction. The slight SCF expression
upregulation we detected in cultured keratinocytes from
these patients might represent the keratinocyte response in
restoring the normal SCF/KIT signaling control of melanocyte
homeostasis. However, hair follicles may be present in the
original donor specimen, as we perform full thickness skin
biopsies (down to the fat layer), in order to be sure not to
damage the epidermal basal cells. Consequently, we may
hypothesize that keratinocyte suffering in piebald trait
patients could be also related to hair follicle keratinocytes
expressing mutated KIT receptors.
Evidence emerging from this study represents a first
step in the transfer of experimental results into the clinical
set.
Patients suffering from piebaldism experience increased
sensitivity to sun exposure in depigmented areas. Moreover,
the cosmetic disfigurement caused by piebaldism, particu-
larly in severe cases, and the absence so far of treatments, has
profound psychological effects on patients and gives rise to
serious emotional stress.
Although topical or systemic medical treatments for
piebaldism are usually unsuccessful, melanocytes taken from
unaffected areas may be introduced by autotransplantation.
The autologous cultured epidermis allows to produce a large
amount of epithelial sheets starting from a small biopsy and
also makes it possible to cover a large body surface in a single
operation (Kumagai and Uchikoshi, 1997; Guerra et al.,
2004). However, the therapeutic outcome of any technology
in the treatment of piebald trait patients is related not only to
the successful result in repigmenting even a large area but
also to the general strategy for restoring pigmentation in the
largest possible number of depigmented areas. Patients
suffering from piebaldism have very extensive depigmented
areas and ask us to treat the entire affected body surface.
Although completely repigmented in the transplanted area,
some patients tell us that their quality of life is not changed,
because they still have white areas.
Mutational analysis of kit gene in the proband is shown
to be predictive regarding the in vitro survival of patient
melanocytes. Indeed, in the case of mutations that correlate
with mild-moderate phenotype, we have treated recipient
areas even 750-fold larger than donor ones, by using
cells both in secondary and tertiary cultures. Moreover, the
patient’s frozen cell bank will allow us to perform
further transplantations. Conversely, mutations that correlate
with a severe phenotype affect melanocyte survival.
In these patients, the greatest recipient sites, which we
have treated were only 250-fold larger than donor
ones, and further operations have required additional donor
sites.
In conclusion, the correlation of severity of kit mutations
and melanocyte behavior in culture allows to plan a
personalized transplantation procedure for each patient.
Communication of timing and extent of treatment possibi-
lities is important for patient compliance and avoids future
disappointment.
MATERIALS AND METHODS
Patients
Seven patients suffering from piebaldism were enrolled in this study
from March 1998 to January 2005 (Table 1). Preliminary data
regarding patients 1, 2, 4, 5, and 6 had been already reported
(Guerra et al., 2004).
Written informed consent was obtained from all patients.
Procedures were in accordance with the ethical standards of the
Committees on Human Experimentation of IDI Institution. The study
was conducted according to Declaration of Helsinki principles.
Cell cultures
Figure 5 summarizes the whole cell culturing process. Full-thickness
skin biopsies (1.2–3.4 cm2) were taken from unaffected body sites
(pubis or buttock), under local anesthesia.
Clinical diagnosis
Skin biopsy
Epidermal cell isolation and plating
1 day after confluence in
vitro reconstituted epidermis:
1 day after confluence in
vitro reconstituted epidermis:
1 day after confluence in
vitro reconstituted epidermis:
1 day after confluence in
vitro reconstituted epidermis:
Primary culture
Positive M/K ratio
Positive M/K ratio
Positive M/K ratio
Positive M/K ratioNegative M/K ratio
Epidermal cell trypsinization
Cell plating Cell freezing
Secondary culture
Graft preparation
First transplantation
Second transplantation
P161, P169, P181,
P160, P129, P154, P185
P169, P181, P160, P129, P154, P185
P169, P160
P129, P154, P185
Needing of further transplantations
Cell thawing and plating
Secondary culture
Tertiary culture
Epidermal cell trypsinization
and plating
New skin biospy Graft preparation
Mutational analysis
Predicted effect
of kit mutation
Patient choice
Figure 5. Flow chart showing the cell culture process. The broken line box
indicates the additional procedures, which will be adopted to improve the
entire technology.
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Epidermal cells were cultured on a feeder-layer of lethally
irradiated 3T3-J2 as described (Guerra et al., 2000, 2003, 2004).
Briefly, biopsies were minced and trypsinized (0.05% trypsin/0.01%
EDTA) at 371C for 3 h. Cells were collected every 30 min, plated
(4 104/cm2) on lethally irradiated 3T3-J2 cells (2.4 104/cm2) and
cultured in 5% CO2 and humidified atmosphere in keratinocyte
growth medium: DMEM and Ham’s F12 media (2:1 mixture)
containing fetal calf serum (10%), insulin (5 mg/ml), adenine
(0.18 mM), hydrocortisone (0.4 mg/ml), cholera toxin (0.1 nM), trii-
odothyronine (2 nM), epidermal growth factor (10 ng/ml), and
glutamine (4 mM).
Quality and safety of culture media and additives were
guaranteed. For bovine serum, the healthy status of the donor herd
was well documented, and freedom at source from bovine spongi-
form encephalopathy (BSE) was ensured.
One day after confluence primary cultures were trypsinized,
plated on 75–175 cm2 flasks at a density of 4 104/cm2, in the
presence of lethally irradiated 3T3-J2 cells (2.4 104/cm2), and
cultivated as above. Grafts destined to the first transplantation were
prepared from secondary cultures 1 day after confluence, as
described (Guerra et al., 2004).
Remaining epidermal cells from primary cultures were frozen
in fetal calf serum containing 10% DMSO. Briefly, cells
were centrifuged into a pellet; the pellet was resuspended in
1 ml/5 106 cells/vial of undiluted fetal calf serum. One milliliter/
vial of fetal calf serum containing 20% DMSO was then added
drop by drop. The vial was put on ice for 10 min to allow the
DMSO to penetrate the cells, and then placed in a 801C
freezer overnight. Finally, cells were put into the liquid nitrogen
container. At least 1 year after the first surgical operation, cells were
defrosted and plated in secondary cultures, at the same cell density
as above and on the feeder-layer of 3T3-J2 fibroblasts. In order to
obtain a sufficient number of cells, secondary cultures were
amplified in tertiary cultures. One day after confluence, tertiary
cultures were utilized to prepare grafts for further operations in P169
and P160 patients. The M/K ratio and the keratinocyte CFE were
determined at each passage of cell amplification (see below). A M/K
ratio till 1/500 was considered favorable for transplantation
procedures.
Surgery
A pretreatment with EMLAs cream (2.5% lidocaine–2.5% prilo-
caine, AstraZeneca S.p.A., Basiglio, MI) under 2-hour occlusion was
performed. Achromic epidermis was removed by using the pulsed
Er:YAG laser (Laser Smart 2940, DEKA M.E.L.A. s.r.l., Calenzano,
Firenze, Italy) with a 2-mm spot-sized hand piece at a setting of
200–500 mJ of energy (Guerra et al., 2003, 2004).
After disepithelialization, the receiving bed was covered with
autologous cultured epidermal sheets. Grafts were secured and
immobilized only by dressings. After 7 days, bandages were
removed. Follow-ups were carried out every 3 months and 18, 24,
36, 48, and 60 months after transplantation.
Achromic and repigmented area sizes were calculated as
described previously (Guerra et al., 2003, 2004).
Serial amplifications of epidermal cells (lifespan cultures)
For serial propagation, epidermal cells from unaffected skin of
piebald trait patients were serially passaged, 1 day after confluence,
at a cell density of 4 104 cells/cm2 and on the feeder-layer
of 3T3-J2 fibroblasts, until they reached senescence. Frozen cells
of piebald patients and of six unrelated controls who did not show
pigmentary disorders (c146, c140, c124, c96, c5850, and c4550)
were utilized in the same culture conditions. Among controls, in
three patients, skin specimens were obtained by mammoplastic
(c146) and abdominoplastic (c5850, c4550) surgery. The remaining
three patients were non-massively (less than 20% of the body
surface) second-degree burnt patients, in whom epidermal cells were
isolated from unaffected skin, in order to treat them using the
autologous in vitro reconstituted epidermis. The mean age of
piebaldism patients and control donors was 22.4 and 28 years,
respectively.
Staining with 3,4-dihydroxyphenylalanine was always performed
on parallel cultures seeded in 24-multiwell plates, 1 day after cells
reached confluence as described (Guerra et al., 2003). The ratio
between melanocytes and total keratinocytes (which include basal
and sovrabasal cells) was evaluated under the phase-contrast
microscope as follows. Under the culture conditions indicated
above, cell density is of approximately 2,000 total keratinocytes/
mm2 (Barrandon and Green, 1987). Thus, to evaluate the M/K ratio,
the number of keratinocytes was divided by the average number
of melanocytes calculated in 10 randomly chosen 2.4-mm2 areas
(approximately the area seen with a magnification  10) of
confluent cultured epidermis (am:ak¼ 1m:xk, where am is the
calculated average number of total melanocytes in 2.4 mm2; ak is
the theoretical number of total keratinocytes in 2.4 mm2;
m¼melanocyte; k¼ keratinocytes).
CFE of keratinocytes at each culture amplification was deter-
mined by plating 1,000 cells on parallel 100-mm dishes, fixing
colonies with 3.7% formaldehyde 12 days later, and staining them
with 1% rhodamine B. Total colonies were calculated as a
percentage of total plated cells; aborted colonies (made by large
and flattened, terminally differentiated cells) were calculated as a
percentage of total colonies.
The number of cell generations performed by cultured
keratinocytes was then calculated using the following formula:
x¼ 3.322 log N/No, where N equals the total number
of cells obtained at each passage and No equals the number
of clonogenic cells plated (Rochat et al., 1994). Clonogenic
cells were calculated from the CFE data (total colonies),
serially determined at each time of culture amplifications. In
those cultures where melanocytes were maintained, the theoretical
number of melanocytes, calculated on the basis of the M/K ratio, was
subtracted from the total number of keratinocytes obtained and
plated.
Western blot analysis of cultured epidermal cells
For immunoblots, confluent epidermal cells in secondary cultures
were lysed for 30 minutes on ice in RIPA buffer, equal amounts of
samples were electrophoresed on 12.5% SDS-polyacrylamide gels,
and Western blots were performed as described (Dellambra et al.,
2000). The following antibodies were utilized: anti-p16INK4a (N20),
anti-p53 (DO-1), anti-p63 (4A4), anti-14-3-3 sigma (N14), anti-SCF
(G-3), all from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); anti-
involucrin from Sigma-Aldrich (St Louis, MO); anti-p21Waf1 was a
kind gift from K Helin (IEO, Milan, Italy).
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Mutational analysis
Genomic DNA was prepared from melanocyte/keratinocyte second-
ary cultures from the seven piebaldism patients. All 21 exons and
flanking intron of the kit gene were amplified by PCR as described
(Giebel et al., 1992). PCR fragments were subjected to direct DNA
sequencing, using the Big dye terminator cycle sequencing ready
reaction kit and an ABI automated sequencing system (Applied
Biosystems, Foster City).
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